cyrilzakka/clinical-trials huggingface dataset:
Use of Hair to Diagnose Breast Cancer

Study FT3.6k-2006 is a single centre (the Mater Hospital, Sydney), blinded trial of a diagnostic test for breast cancer, with outcomes compared to the gold standard of screening mammogram followed by biopsy where required. This study aims to perform X-ray diffraction analysis of coded hair samples from women with a documented breast health status, to validate the findings of James et al (Nature 398: 33-4, 1999; Int J Cancer 114: 969-72, 2005) who showed that the presence of breast cancer could be detected using synchrotron-derived x-ray diffraction of human hair (scalp or pubic). The aim is also to characterise the sensitivity and specificity of the hair test in detecting breast cancer in a screening setting, and to determine the significance of a positive hair test and a negative mammogram.

The test has the potential to improve the diagnostic (and consequently therapeutic) paradigm for breast cancer.

Women attending a radiology clinic in the Mater Hospital, Sydney, for a mammogram will be invited to participate in the study. A few hairs will be cut from their head or pubic region, put into a coded container and sent to the sponsor for analysis by synchrotron-x-ray diffraction. Although an imperfect standard for a variety of reasons, mammography is the standard screening assay, and confirmation of the pathology of the lesions found by mammography is carried out by biopsy. This will be the standard to which the hair test results will be compared. A negative mammogram will confirm a negative hair test, but a negative mammogram combined with a positive hair diffraction test will need a different approach. In the event of a positive hair test and a negative second read of the mammogram, the patient will be contacted by the referring practitioner. Patients in this category will be offered a breast MRI. A negative breast MRI under these circumstances will be classified as a true negative.

Eligibility Criteria:
Inclusion Criteria:

* Adult women (aged \>20) who are undergoing mammography at the Mater Hospital, Sydney, and
* Who are willing and able to provide informed consent; and
* Who have usable scalp and/or pubic hair

Exclusion Criteria:

* Women who have dyed or permed their scalp hair within the previous 6 weeks and whose pubic hair is unavailable;
* Women with a history of breast cancer ever or other cancers (excluding non-melanoma skin cancer and CIN \[cervical intra-epithelial neoplasia\]) within 5 years.
Bioequivalence Study of Ezetimibe Tablets Under Fasting Conditions in Healthy Subjects

The fasting bioequivalence test adopts the experimental design of single center, single oral administration, random, open, two sequence, two cycle crossover and self-control.

To investigate the in vivo pharmacokinetic characteristics of ezetimibe tablets (specification 10mg) in Chinese healthy subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of ezetimibe tablets produced by Changzhou Pharmaceutical Factory Co., Ltd. and the licensee MSD Pharma (Singapore) PTE. Ltd. To study the safety of single oral ezetimibe tablets (specification 10mg) in Chinese healthy subjects.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female aged 18 and above.
* The body mass index is in the range of 18.6-28.5 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.
* The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test.
* The subjects have no family planning within 3 months and could select contraceptive method.
* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.

Exclusion Criteria:

* Being allergy to the study medications, smoking, alcohol abuse.
* Participation in another clinical trial within 3 months.
Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders

The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of patients affected by osteogenesis imperfecta (OI), and both compared with a control sample with typical development.

The secondary aim is to study cortical activity at rest, by means of electroencephalography (EEG), to explore frequencies and time course of EEG responses. Moreover, the relationship between EEG activity and neuropsychological, dispositional and subjective measures will be explored through correlational analyses.

Study procedure includes: 1. Eligibility assessment according to inclusion and exclusion criteria. 2. Administration of questionnaires and scales for the characterization of cognitive and psychological features related with BMD/DMD and OI : Wechsler Intelligence Scale for Children 4th Edition (WISC-IV), Raven's Progressive Matrices; NEPSY-II; The Child Behavior Checklist (CBCL); PedsQL; Toronto Alexithymia Scale (TAS-20); Emotion Regulation Questionnaire (ERQ); Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA); Multidimensional Assessment of Interoceptive Awareness (MAIA); Body Shape Questionnaire (BSQ-14); and the Autism Spectrum Quotient (AQ, adult or child version) 3. Administration of experimental tasks. The Comfort-Distance Task (CDT) to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality by means of head-mounted displays (OCULUS ©2024 Meta). Interoceptive accuracy will be measured through a modified version of the heartbeat counting task. An emotional priming task will be administered in order to measure emotion processing, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming.

All the tasks will be performed in a counterbalanced order, for an overall duration of about 40 minutes.

4. Recording of resting state EEG will be collected.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).
* Patients diagnosed with osteogenesis imperfecta.
* Control group: participants without any neurological or psychiatric disorder

Exclusion Criteria:

* presence of comorbid diagnoses,
* sensory deficit
* specific condition that could prevent the application of the tests and tasks under study, such as: a) the need for PEG; b) the need for tracheostomy; c) the need for assisted ventilation.
* cognitive level lower than 60.
Phase III Study to Evaluate the Efficacy and Safety of AD-209

The purpose of this study is to evaluate the efficacy and safety of AD-209

Condition or disease : hypertension

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Other inclusions applied

Exclusion Criteria:

* Orthostatic hypotension with symptom
* Other exclusions applied
Diclofenac Potassium With or Without Vaginal Dinoprostone Prior to Hysterosalpingography

The aim of our study is to determine the efficacy of oral diclofenac potassium with or without vaginal dinoprostone prior to hysterosalpingography in primarily infertile patients on the pain scores during HSG.

hysterosalpingography is a diagnosis procedure in the evaluation of infertile women and considered to be the traditional and the gold standard in the assessment of the patency of the fallopian tubes. The major disadvantage of hysterosalpingography is pain. In a study reported the patients complained of moderate to severe pain during the procedure. It is reported that some patients undergoing hysterosalpingography was more stressful and anxiety and effect on pain scores.

Eligibility Criteria:
Inclusion Criteria:

* primary infertility female came for HSG

Exclusion Criteria:

* any patient has contraindication to HSG
Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

This study is conducted to assess the efficacy and safety of SK-1403 in Hemodialysis Patients with Secondary Hyperparathyroidism. In the first treatment period, the efficacy of SK-1403 is assessed after 18 weeks of treatment with SK-1403 individually dose-adjusted . Safety is also assessed during this period. Patients who completed the first treatment period proceed to the second treatment period and receive the treatment with SK-1403 for 34 weeks. Efficacy and safety of SK-1403 are also assessed during this period.


Eligibility Criteria:
Inclusion Criteria:

* Average serum PTH\>240 pg/mL during 2 weeks at the screening
* Serum corrected Ca≧8.4 mg/dL at the screening
* Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration

Exclusion Criteria:

* Primary hyperparathyroidism
* Severe liver disease
* Severe Cardiac disease
* History or family history of Long QT syndrome
* Malignant tumor
* Uncontrolled diabetes mellitus
* Uncontrolled hypertension
* A history of severe drug allergy
Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18 years old to 75 years old, male and female is ok.
* Esophageal squamous cell carcinoma diagnosed by histopathology and immunohistochemistry. At least one treated measurable lesion (spiral CT scan length ≥10mm, in line with RESCIST version 1.1 standard requirements);
* Patients with advanced esophageal cancer treated by radiotherapy and treatment;
* ECOG PS Rating: 0-1 points;
* Expected survival ≥12 weeks;
* Without molecular targeted drug therapy.
* The main organ function is normal, that is to meet the following criteria:

Blood test:a.HB≥90 g/L；b.ANC≥1.5×109/L；c.PLT ≥80×109/L； Biochemical tests:a.ALB≥30g / L；b. ALT和AST\<2ULN；ALT and AST \<2ULN;c.TBIL≤1.5ULN；Plasma Cr ≤ 1.5ULN;

* Subjects volunteered to join the study, signed informed consent, compliance, with follow-up.
* Researchers believe that patients can benefit.

Exclusion Criteria:

* Patients who have been confirmed to be allergic to apatinib and / or its excipients;
* Patients with uncontrollable hypertension (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg, despite optimal drug therapy), with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).According to NYHA standard, grade Ⅲ \~ Ⅳ heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) \<50%.
* Patients with a clear tendency to gastrointestinal bleeding, including the following: localized ulcer lesions, and fecal occult blood (++) can not be grouped; 2 months with black, hematemesis history;
* Coagulation dysfunction (INR\> 1.5, APTT\> 1.5 ULN), with bleeding tendency;
* (Eg, no swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.) that affect the absorption of oral medications;
* The patients with active brain metastases(without medical control) , cancer meningitis, spinal cord compression, or screening of imaging CT or MRI examination found that the brain or pia mater disease (21 days before the completion of treatment and symptoms of stable brain Metastasis patients can be grouped, but the need for transcranial MRI, CT or intravenous angiography, confirmed as no cerebral hemorrhage symptoms)
* Pregnant or lactating women
* Subject with other malignancies within 5 years(except the skin basal cell carcinoma and cervical in situ cancer that have already cured )
* Subject with a history of psychiatric abuse and who can not be abused or have mental disorders;
* Subject who participated in other drug clinical trials within 4 weeks.
* Subject who have received VEGFR inhibitors such as sorafenib, sunitinib;
* According to the investigator's judgment, there are serious illnesses that compromise the patient's safety or affect the patient's completion of the study;
* Researchers think it is not suitable for inclusion.
A Short, Animated Storytelling Video to Boost Psychological Capital

This study will evaluate the effect of a short, animated storytelling intervention video on positive psychological capital intervention on immediate and medium-term psychological capital and related constructs, gratitude and happiness. We will also measure voluntary engagement with the content of the short, animated storytelling intervention video on positive psychological capital.

In this 4-armed, parallel, randomized controlled trial, 10,000 adult, US participants will be randomly assigned to (1) a short, animated storytelling intervention video on positive psychological capital followed by the psychological capital , gratitude and happiness surveys (2) the surveys only, (3) an attention placebo control video followed by the before mentioned surveys, and (4) an arm that is exposed to neither the video nor the surveys. Two weeks later, participants in all four arms will complete all of the surveys.

The primary outcome is psychological capital (immediate and medium-term). Secondary outcomes are gratitude and happiness (immediate and medium-term) as well as voluntary engagement with the short, animated storytelling video content.


Eligibility Criteria:
Inclusion Criteria:

* Registration with the Prolific platform

Exclusion Criteria:

* none
Dose-Dense Therapy in Aggressive Lymphoma

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.

Eligibility Criteria:
Inclusion Criteria:

* 18 and 70 years of age
* Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
* Measurable disease
* All stages

Exclusion Criteria:

* Lymphoblastic or Burkitt histology
* CNS-disease
* HIV-positive
* pregnant or lactating women
* Pretreatment
* Other malignancy
* Concomitant diseases that forbid chemotherapy
Ankle Kinesio Taping on Balance and Functional Performance in Obese Females.

Obesity is one of the most dangerous factors affecting the joints, which must be prevented due to arthritis and the long-lasting, tiring effects that affect a person's life \[1\], The most important of these are foot problems due to weight and excess pressure, It is also one of the factors that greatly affects walking movement because it increases the load on joint movement, This increases the risk of musculoskeletal diseases.

It had been reported that obese subjects have a higher prevalence of falls and ambulatory stumbling or a loss of balance than their non-obese counterparts. Excess weight increases the stress within the bones, joints, and soft tissues, resulting in impaired musculoskeletal function. such as abnormal mechanics of the body. These impairments, such as impaired balance, gait, strength, sensory function, and neuromuscular function have been identified as strong risk factors for falls.

Participants that are eligible to participate to the study will be distributed into two groups: Group A will receive ankle kinesiotaping on the dominant leg. While, Group B will receive placebo kinesiotaping on the dominant leg. The treatment duration will be 6 weeks for both groups.

Eligibility Criteria:
Inclusion Criteria:

* Female students between 18 and 25 years old
* BMI of 30 kg/ m2 or more

Exclusion Criteria:

* Orthopedic or neurosurgery injury past 6 months
* Ankle edema
* Skin allergy to the tape
* Abnormalities of the nervous system
* Any previous history of injury
* Use of medication in the past 3 months
* Regular physical activity at least three times a week
Effect of Denileukin Diftitox on Immune System in CTCL Patients

This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma.

Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

Although the etiology of CTCL is not fully understood, it is believed to be a malignancy proliferation of a "memory" T-cell in the context of Th2-type cytokine profile and suppressed cytotoxic T-cell (CTL) immunity. T-regulatory (T-regs) cells may be important in CTCL in the setting of immunotherapy. Removal of T-regs would result in enhanced immune responses in vitro, which may translate into augmentation of the anti-tumor immune response and durable clinical responses in vivo. We propose to evaluate effects of ONTAK on the T-reg cell subset in patients undergoing routine therapy with ONTAK. We will evaluate T-reg subsets in peripheral blood and tumor tissues from the patients both phenotypically using multi-color FACS analysis and confocal microscopy, and functionally in MLRs and ELISpot assays with baseline, day 5 and 19 blood samples in up to four cycles.

Completion date provided represents the completion date of the grant per OOPD records

Eligibility Criteria:
Inclusion Criteria:

* 18 and older
* diagnosed with CTCL
* able and willing to provide informed consent
* will be receiving denileukin diftitox per standard guidelines

Exclusion Criteria:

* prior history of receiving Ontak
* pregnancy
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.

Patients are randomized to receive either ribavirin or a placebo for 7 days. At the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.

Eligibility Criteria:
Inclusion Criteria:

You may be eligible for this study if you:

* Are 12 years of age or older.
* Are not pregnant.
* Agree to practice sexual abstinence or use accepted barrier methods of birth control/contraception.
* Are not breast-feeding.
* Have a positive blood test for hantavirus.
* Have symptoms suggestive of hantavirus illness.

Exclusion Criteria:

You will not be eligible for this study if you:

* Have severe low blood count (anemia).
* Have a diagnosis of other respiratory viruses (influenza, RSV, etc.).
* Have group A Streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia.
* Are HIV positive.
* Have cancer.
* Have had any period of irregular heartbeat.
* Have had chemotherapy or other drugs that suppress the immune system within 30 days.
* Have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.)
* Have taken by mouth or injection corticosteroids equivalent to approximately 0.5 mg/kg prednisone.
* Have taken any experimental drug within 30 days prior to enrollment.
Improving Safety, Patient Experience and Equity Through Shared Decision-making Huddles in Labor

To evaluate the effectiveness of an existing quality improvement (QI) training program known as TeamBirth, using a randomized stepped-wedge hybrid type II study design, to (a) decrease nulliparous term singleton vertex (NTSV) cesarean birth (CB) across all birthing people, and specifically for Black birthing people, and (b) increase shared decision-making (SDM), (c) improve patient experience of respectful care. TeamBirth uses a train-the-trainer model to implement patient-participatory shared decision-making on Labor and Delivery (L\&D) units, with the goal of decreasing unwanted and unnecessary interventions and improving patient experiences and outcomes for labor and birth.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* English or Spanish speaking
* Gave birth to a live-born infant after laboring

Exclusion Criteria:

* Speaks a language other than English or Spanish
* Under the age of 18
* Gave birth to a nonliving infant
* Cesarean delivery without labor
Effect of Beet Juice Supplementation on Vascular and Inspiratory Muscle Function

Older adults with coronary artery disease (CAD) have impaired vascular and inspiratory muscle function. The objective of this study is to examine the effect of beet juice supplementation on vascular and inspiratory muscle function in older adults with CAD.


Eligibility Criteria:
Inclusion Criteria:

* Adults with coronary artery disease (CAD) based on an angiogram \>50% stenosis in any major epicardial vessel or history of myocardial infarction or history of coronary revascularization.
* Considered to have stable CAD on optimal medical therapy
* 60 to 85 years of age
* Men and women (women must be postmenopausal either natural or surgical)
* Able to give consent

Exclusion Criteria:

* Ejection fraction \<50%, unstable angina, recent myocardial infarction within 6 months
* Coronary revascularization, including percutaneous coronary intervention and coronary artery bypass graft or thoracic surgery within 6 months.
* Stroke, obstructive pulmonary disease, hepatitis B, C, HIV, seizures, or other relevant on-going or recurrent illness
* Individuals that have participated in respiratory training within the last 12 months or cardiac rehabilitation within the last 6 months
* Uncontrolled hypertension
* Use of tobacco products including smoking traditional or e-cigarettes
* Use of hormone replacement therapy in women or men (e.g., estrogen, progesterone or testosterone)
* Regular aerobic exercise training
* Unwilling to stop using mouthwash at least 1 week before the start of the study and during study participation
* Unwilling to remain weight stable during study participation